Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for sta...
October 17, 2026
Share
Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial.